Cargando…
Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab
BACKGROUND: Although a recent randomized clinical trial has demonstrated that the objective response rate to nivolumab for metastatic gastric cancer was 11.2%, there was no patients confirmed complete response. Herein, we report on a case of liver metastasis arising from early gastric cancer in whic...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033840/ https://www.ncbi.nlm.nih.gov/pubmed/29978335 http://dx.doi.org/10.1186/s40792-018-0479-3 |
_version_ | 1783337751746183168 |
---|---|
author | Namikawa, Tsutomu Ishida, Nobuko Tsuda, Sachi Fujisawa, Kazune Munekage, Eri Iwabu, Jun Munekage, Masaya Uemura, Sunao Tsujii, Shigehiro Maeda, Hiromichi Kitagawa, Hiroyuki Kobayashi, Michiya Hanazaki, Kazuhiro |
author_facet | Namikawa, Tsutomu Ishida, Nobuko Tsuda, Sachi Fujisawa, Kazune Munekage, Eri Iwabu, Jun Munekage, Masaya Uemura, Sunao Tsujii, Shigehiro Maeda, Hiromichi Kitagawa, Hiroyuki Kobayashi, Michiya Hanazaki, Kazuhiro |
author_sort | Namikawa, Tsutomu |
collection | PubMed |
description | BACKGROUND: Although a recent randomized clinical trial has demonstrated that the objective response rate to nivolumab for metastatic gastric cancer was 11.2%, there was no patients confirmed complete response. Herein, we report on a case of liver metastasis arising from early gastric cancer in which a complete clinical response was achieved to nivolumab as third-line therapy. CASE PRESENTATION: A 77-year-old man was referred to Kochi Medical School Hospital for the treatment of liver metastases from gastric cancer. The patient had undergone laparoscopic total gastrectomy with regional lymph node dissection 30 months prior for early gastric cancer, with a final diagnosis of T1N0M0, stage IA. The patient developed solitary splenic metastasis measuring 42 mm 28 months later and underwent splenectomy because there was no evidence of further metastatic lesions in any other organ. The patient was treated with S-1 plus oxaliplatin based on negative immunohistochemical staining of the resected specimens for human epidermal growth factor receptor 2 (HER2). Four months after the splenectomy, the patient developed multiple liver metastases and was treated with ramucirumab plus paclitaxel. Because of disease progression, the patient was administered 3 mg/kg, i.v., nivolumab every 2 weeks. After 4 cycles of systemic treatment using nivolumab, abdominal computed tomography revealed marked shrinkage of the liver metastases. After 12 cycles of nivolumab, the liver metastases had disappeared completely. The patient did not develop any adverse reactions, including immune-reactive adverse events, during treatment. The patient continues to receive nivolumab, and there is no evidence of disease recurrence in the 8-month period since starting nivolumab. CONCLUSIONS: To the best of our knowledge, this is the first case report in the English literature of a gastric cancer patient achieving a complete clinical response to nivolumab, and highlights the potential for successful treatment of metastatic gastric cancer using nivolumab. |
format | Online Article Text |
id | pubmed-6033840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-60338402018-07-24 Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab Namikawa, Tsutomu Ishida, Nobuko Tsuda, Sachi Fujisawa, Kazune Munekage, Eri Iwabu, Jun Munekage, Masaya Uemura, Sunao Tsujii, Shigehiro Maeda, Hiromichi Kitagawa, Hiroyuki Kobayashi, Michiya Hanazaki, Kazuhiro Surg Case Rep Case Report BACKGROUND: Although a recent randomized clinical trial has demonstrated that the objective response rate to nivolumab for metastatic gastric cancer was 11.2%, there was no patients confirmed complete response. Herein, we report on a case of liver metastasis arising from early gastric cancer in which a complete clinical response was achieved to nivolumab as third-line therapy. CASE PRESENTATION: A 77-year-old man was referred to Kochi Medical School Hospital for the treatment of liver metastases from gastric cancer. The patient had undergone laparoscopic total gastrectomy with regional lymph node dissection 30 months prior for early gastric cancer, with a final diagnosis of T1N0M0, stage IA. The patient developed solitary splenic metastasis measuring 42 mm 28 months later and underwent splenectomy because there was no evidence of further metastatic lesions in any other organ. The patient was treated with S-1 plus oxaliplatin based on negative immunohistochemical staining of the resected specimens for human epidermal growth factor receptor 2 (HER2). Four months after the splenectomy, the patient developed multiple liver metastases and was treated with ramucirumab plus paclitaxel. Because of disease progression, the patient was administered 3 mg/kg, i.v., nivolumab every 2 weeks. After 4 cycles of systemic treatment using nivolumab, abdominal computed tomography revealed marked shrinkage of the liver metastases. After 12 cycles of nivolumab, the liver metastases had disappeared completely. The patient did not develop any adverse reactions, including immune-reactive adverse events, during treatment. The patient continues to receive nivolumab, and there is no evidence of disease recurrence in the 8-month period since starting nivolumab. CONCLUSIONS: To the best of our knowledge, this is the first case report in the English literature of a gastric cancer patient achieving a complete clinical response to nivolumab, and highlights the potential for successful treatment of metastatic gastric cancer using nivolumab. Springer Berlin Heidelberg 2018-07-05 /pmc/articles/PMC6033840/ /pubmed/29978335 http://dx.doi.org/10.1186/s40792-018-0479-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Case Report Namikawa, Tsutomu Ishida, Nobuko Tsuda, Sachi Fujisawa, Kazune Munekage, Eri Iwabu, Jun Munekage, Masaya Uemura, Sunao Tsujii, Shigehiro Maeda, Hiromichi Kitagawa, Hiroyuki Kobayashi, Michiya Hanazaki, Kazuhiro Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
title | Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
title_full | Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
title_fullStr | Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
title_full_unstemmed | Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
title_short | Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
title_sort | successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033840/ https://www.ncbi.nlm.nih.gov/pubmed/29978335 http://dx.doi.org/10.1186/s40792-018-0479-3 |
work_keys_str_mv | AT namikawatsutomu successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT ishidanobuko successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT tsudasachi successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT fujisawakazune successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT munekageeri successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT iwabujun successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT munekagemasaya successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT uemurasunao successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT tsujiishigehiro successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT maedahiromichi successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT kitagawahiroyuki successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT kobayashimichiya successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab AT hanazakikazuhiro successfultreatmentoflivermetastasesarisingfromearlygastriccancerachievedclinicalcompleteresponsebynivolumab |